Infinatas BioPharm Insight Achieves Record Growth in 2012

Norwood, MA (PRWEB) February 04, 2013

Infinatas BioPharm Insight capped another year of global expansion in 2012. BioPharm Insight offers subscribers the unique combination of comprehensive market analytics, a database of key industry contacts and proprietary forward-looking intelligence uncovered by an independent team of investigative journalists.


Ruth McHenry, Managing Director of Infinata, said, BioPharm Insight continues its aggressive growth to meet the needs of industry professionals. Every day we work closely with our customers to understand and solve the challenges they face. I am so proud to say that in 2012 we met and exceeded all targeted areas of growth.


New Features & Functionalities


New User Interface BioPharm Insights completely redesigned user interface (UI) features a customizable homepage, easier navigation, and interactive charts and graphs. These enhancements allow subscribers to filter data and intelligence to fit their needs, allowing them to identify business opportunities as soon as they arise.


Increased Scope of Data In addition to a new UI, BioPharm Insight continued to improve the scope of data provided to subscribers with the addition of:


FDA Approves Two Anti-Obesity Drugs in 2012 but Approval from EMA Unlikely

EMA’s cynicism towards anti-obesity drugs will hinder Belviq and Qsymia EU approvals

October 22, 2012 – Norwood, MA – This summer brought two new anti-obesity drugs to the market. On June 27th, the FDA approved Belviq (lorcaserin), a 5-HT2C receptor agonist, from Arena Pharmaceuticals, the first prescription weight-loss drug to hit the US market in more than a decade. Arena submitted a Marketing Authorization Application (MAA) for Belviq to the European Medicines Agency (EMA) in 2012. The second anti-obesity drug FDA approved this year was Vivus’ Qsymia on July 18th. The company filed an MAA in December 2010. The EMA’s Committee for Medicinal Products for Human Use is unlikely to recommend approval, Vivus said.

Qsymia and Belviq are unlikely to see EU approval for several years, according to the experts interviewed by BioPharm Insight. European regu¬lators will wait for US post-marketing data or results from cardiovascular (CV) outcomes trials. Additionally, the EMA has not faced the same degree of organized political and patient advocacy pressure as the FDA. The EMA still per¬ceives obesity as a psychobehavioral disorder rather than a risk factor for diabetes and hypertension. While Belviq’s safety profile is superior to Qsymia, its efficacy is likely to be scrutinized considering the EMA’s cynicism toward the role of anti-obesity drugs.

Another anti-obesity drug on the path to approval is Orexigen Therapeutics’ Contrave, which received a complete response letter in January 2011. The FDA expressed concern about the drug’s CV safety profile when used long-term in obese and overweight patients. The agency requested the company to conduct a study to assess the occurrence of major adverse cardiovascular events (MACE). Orexigen has thus initiated a Phase III study called LIGHT. NDA resubmission is expected in 2Q/3Q13.

Still in development, Orexigen’s other anti-obesity candidate, which is in Phase II, has completed enrollment in its second Phase IIb trial, a 24-week study in healthy, nondiabetic, obese patients. On September 22nd, Zafgen, a Massachusetts-based private company, announced data from two Phase Ib studies of beloranib, a methionine aminopeptidase 2 (MetAP2) inhibitor. It showed rapid weight loss, reductions in body fat and improvements in cardiovascular disease risk markers in severely obese women.

Sign up for a free trial to download the full report.



Hopeful New Direction for Alzheimers Research, From the February 2013 Harvard Women’s Health Watch

Boston MA (PRWEB) February 04, 2013

None of the current treatments for Alzheimer’s can stop the disease or slow the process that leads to its theft of memory and personality. A new direction in Alzheimers research, highlighted in the February 2013 issue of the Harvard Women’s Health Watch, may someday change that.

For the past 20 or even 30 years weve been focused on treating the end stage of Alzheimers, and we must shift our paradigm to start thinking about prevention, says Dr. Reisa Sperling, director of the Center for Alzheimers Research and Treatment at Harvard-affiliated Brigham and Womens Hospital.

Dr. Sperling and other researchers are focusing on several approaches for early intervention, before Alzheimer’s affects memory, thinking, and behavior. Three key areas include:

Bel Marra Health Reports on a New Study: Negative and Traumatic Memories May Soon Be Able to Be Erased Using New Science

Toronto, ON (PRWEB) January 28, 2013

Bel Marra Health, well known for offering high-quality, specially formulated vitamins and nutritional supplements, is reporting on a new study that outlines how traumatic memories could soon be erased using a new science.

As Bel Marra Health reports in its article (, Karim Nader created a traumatic memory in rats by putting them in an isolation cubicle, playing a tone and then delivering a small electrical shock to their feet.

After creating the initial traumatic memory, the rat associates the tone with an unpleasant experience. After this initial traumatic experience, when the rat hears the tone it freezes, showing fear. The next step in Naders experiment involved placing the rat back in the isolation chamber and playing the tone which brings the traumatic memory back. Nader then experiments with drugs that are responsible for blocking chemical processes that are responsible for restoring memories, which is a normal brain function.

This allows the old traumatic memory to be replaced by the new memory of the tone with no electrical shock. The rat is then placed back in the isolation cubicle where the tone is once again played. The rat no longer has a reaction of fear to the sound as his traumatic memory seems to have been replaced by a new one.

As the Bel Marra Health article reads, the point of this research is to see if its possible to erase memories in a rat. Additionally, Nader states that memories can become un-stored, altered and strengthened.

Understanding all of the chemical processes that are part of normal brain function, including the chemical processes involved in memory is important for understanding new treatment options that may be beneficial for individuals suffering from bad memories.

Spokesperson for Bel Marra Health Dr. Victor Marchione says, There are many diseases that negatively affect brain function and diminish brain health. These disorders include: dementia, Alzheimers disease, schizophrenia and PTSD, among others. Nader believes that memory disruption; similar to what was shown in his recent research, may help to treat various mental health disorders.

The findings from Karim Naders research are supported by research conducted by Thomas Agren, who is a doctoral candidate at Uppsala University. Agren found that it was possible to erase newly formed memories from the human brain.

(SOURCE: PLoS One, Non-hebbian learning implementation in light-controlled resistive memory devices. Dec 14, 2012)

Bel Marra Health, as the distributor of Smart Pill, offers high-quality vitamins and nutritional supplements in formulations designed to address specific health concerns. All ingredients are backed with scientific evidence. Every product is tested for safety, quality, and purity at every stage of the manufacturing process. Furthermore, Bel Marra Health products are produced only in Health Canada approved facilities, going that extra mile to ensure our health conscious customers are getting top quality products. For more information on Bel Marra Nutritionals visit or call 1-866-531-0466.

Alzheimer’s Disease (Understanding Disease: Neurology)

Get the facts on Alzheimer’s disease with this 100%-accurate animated video. Part of Focus Apps’ Understanding Disease: Neurology series, the Alzheimer’s Disease app explains the function, anatomy, and disease of the brain. It also describes in detail the various forms of the disease, diagnostic procedures, and treatment options. It also lists patient-care guidelines for caretakers and for those who are coping with the disease.

Treatment for early Alzheimer’s disease

Treatment for early Alzheimer’s disease Evidence shows unique dietary approach effective in early Alzheimer’s disease Research shows people with Alzheimer’s have low levels of certain nutrients needed to keep the brain healthy New product for the dietary management of early Alzheimer’s disease A new medical nutrition product for the dietary management of early Alzheimer’s disease will be launched today in the UK after more than ten years of research and clinical trials that show it could have significant benefits for those diagnosed with early-stage disease. Souvenaid (a 125ml once-daily drink) was developed by scientists at Massachusetts Institute of Technology (MIT) and medical nutrition company Nutricia. It contains a unique combination of nutrients that are naturally present in food, at levels difficult to achieve from diet alone. This includes omega-3 polyunsaturated fatty acids (docosahexaenoic acid, DHA; eicosapentaenoic acid, EPA), uridine (as uridine monophosphate, UMP) and choline, together with phospholipids and B vitamins. Dementia affects over 800000i people in the UK and Alzheimer’s disease is the most common form. In an aging population, ministers and experts have acknowledged the need to diagnose people earlier, to help manage the symptoms and plan for the future. The loss of connections in the brain (synapses) is one of the key features of early Alzheimer’s disease, and a combination of nutrients is required in the process of making new connections
Video Rating: 5 / 5

I’m a Caregiver, but Feel Like a Nurse!

I’m a Caregiver, but Feel Like a Nurse!
Could you manage the feeding tube inserted in your father’s stomach? Would you be able to change bandages after your mother’s heart surgery? Do you know how to give injections or check someone’s blood oxygen level? If you’re a caregiver, you may be expected to do all that — and more — as part of your daily routine….
Read more on AARP News


Life Lessons from an Alzheimer’s Caregiver
So when White learned that her father had Alzheimer’s disease, she found the transformation from loved one to caregiver only natural.

But it’s a process she couldn’t have survived, she says, without a support network that included the Alzheimer’sAssocation of Western New York.
Read more on Foreveryoungwny